Available Cancer Studies

For information on all clinical trials available across the United States, visit clinicaltrials.gov

Phase I Trials

LS-P-POST: A study for patients with advanced gastroesophageal cancer. The main purpose of this study is to find out how the cancer responds to MSB0010718C (an investigational drug) and the side effects both good and bad.
PI: Howard Safran, MDSites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study

LS-P-SGN MDS: A phase 1/2 study of Vadastuximab talirine (SGN-CD33A) in combination with Azacitidine in patietns with previously untreated international prognostic scoring system (ipSS) intermediate -2 or high-risk myelodysplastic syndrome (MDS)
PI: John Reagan, MD
Site: Rhode Island Hospital (RIH) and The Miriam Hospital (TMH)
Learn more about this study

LS-P-CHUGAI: A phase 1 dose escalation and cohort expansion study ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors
PI: Howard Safran, MD  
Site: Rhode Island Hospital
Learn more about this study

LS-P-Regeneron
A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies – Protocol R2810-ONC-1423.
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study

LS-P-CC-486-DLBCL-001: A phase one, open-label, multicenter trial of oral Azacitidine (CC-486) plus R-CHOP in subjects with high risk (IPI 3 Or More) previously untreated diffuse large B-cell lymphoma or grade 3B follicular lymphoma
PI: John Reagan, MD
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study

LS-P-ADXS142-03: A phase 1-2 dose-escalation and safety study of ADXS31-142 alone and of ADXS31-142 in combination with Pembrolizumab (MK-3475) in patients with previously treated metastatic castration-resistant prostate cancer 
PI: Anthony Mega, MD 
Site: The Miriam Hospital
Learn more about this study

LS-P-M14-360: A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo Controlled Study of the Efficacy and Tolerability of Veliparib in Combination with Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects with Stage III Non-Small Cell Lung Cancer (NSCLC)
PI: Thomas DiPetrillo, MD
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study

LS-P-JSBA: A Phase I Study of LY2801653 in Patients with Advanced Cancer
 
PI: Ariel Birnbaum, MD 
Sites: Rhode Island Hospital, The Miriam Hospital
 
Learn more about this study

LS-P-Trap001: A Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study

 

LS-P-CC-486-DLBCL-001: A phase one, open-label, multicenter trial of oral Azacitidine (CC-486) plus R-CHOP in subjects with high risk (IPI 3 Or More) previously untreated diffuse large B-cell lymphoma or grade 3B follicular lymphoma
PI: John Reagan, MD
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study

Solid Tumors

LS-P-POST: A study for patients with advanced gastroesophageal cancer. The main purpose of this study is to find out how the cancer responds to MSB0010718C (an investigational drug) and the side effects both good and bad.
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study

LS-P-Trap001: A Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study

LS-P-CHUGAI: A phase 1 dose escalation and cohort expansion study ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors 
PI: Howard Safran, MD  
Site: Rhode Island Hospital
Learn more about this study

LS-P-JSBA: A Phase I Study of LY2801653 in Patients with Advanced Cancer
 
PI: Ariel Birnbaum, MD 
Sites: Rhode Island Hospital, The Miriam Hospital
 
Learn more about this study

LS-P-Regeneron
A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies – Protocol R2810-ONC-1423.
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study

Anal

BrUOG 276: A phase I/II evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for anal cancer 
PI: Howard Safran, MD
 
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study 

LS-P-CHUGAI: A phase 1 dose escalation and cohort expansion study ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors 
PI: Howard Safran, MD  
Site: Rhode Island Hospital
Learn more about this study

LS-P-Regeneron
A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies – Protocol R2810-ONC-1423.
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital

Bladder

LS-P-ABL: A phase III, open-label, multicenter, randomized study of Atezolizumab (Anti-PD-L1 Antibody) versus observation as adjuvant therapy in patients with PD-L1-selected, high risk muscle invasive bladder cancer after cystectomy (WO29636) 
PI: Anthony Mega, MD 
Site: The Miriam Hospital
Learn more about this study

LS-P-CHUGAI: A phase 1 dose escalation and cohort expansion study ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors 
PI: Howard Safran, MD  
Site: Rhode Island Hospital
Learn more about this study

LS-P-Regeneron
A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies – Protocol R2810-ONC-1423.
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital

Blood Disorders (Hematology)

Myelodysplastic syndrome (MDS)

LS-P-SGN MDS: A phase 1/2 study of Vadastuximab talirine (SGN-CD33A) in combination with Azacitidine in patietns with previously untreated international prognostic scoring system (ipSS) intermediate -2 or high-risk myelodysplastic syndrome (MDS)
PI: John Reagan, MD
Site: Rhode Island Hospital (RIH) and The Miriam Hospital (TMH)

 

Brain

A071102: A Phase II/III Randomized Trial Of Veliparib Or Placebo In Combination With Adjuvant Temozolomide In Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
PI: Heinrich Elinzano, MD
Site: Rhode Island Hospital
 
LS-P-Trap001: A Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital
 

LS-P-CHUGAI: A phase 1 dose escalation and cohort expansion study ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors
PI: Howard Safran, MD 
Site: Rhode Island Hospital
Learn more about this study

LS-P-Regeneron
A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies – Protocol R2810-ONC-1423.
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital

Breast

Alliance A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (CT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
PI: Kara Leonard, MD
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study

LS-P-COMB: A multistage Phase II study evaluating the safety and efficiency of Combimetinib in combination with Paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer 
PI: Mary Anne Fenton, MD 
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study 

LS-P-Trap001: A Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital
 

LS-P-PALLAS: Palbociclib Collaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer 
PI: Mary LoPresti, DO 
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study

LS-P-CHUGAI: A phase 1 dose escalation and cohort expansion study ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors 
PI: Howard Safran, MD  
Site: Rhode Island Hospital
Learn more about this study

CARG 11127: Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
PI: Mary Anne Fenton, MD
Sites: Rhode Island Hospital, The Miriam Hospital

Learn more about this study 

LS-P-Regeneron
A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies – Protocol R2810-ONC-1423.
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital
 
NSABP B-51
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
PI: Kara Leonard, MD
Site: Rhode Island Hospital (RIH) and The Miriam Hospital (TMH)
Learn more about this study
 

 

Esophageal

LS-P-POST: A study for patients with advanced gastroesophageal cancer. The main purpose of this study is to find out how the cancer responds to MSB0010718C (an investigational drug) and the side effects both good and bad.
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital
 
LS-P-Trap001: A Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital
 

LS-P-Javelin 100: A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction 
PI: Howard Safran, MD 
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study  

LS-P-CHUGAI: A phase 1 dose escalation and cohort expansion study ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors 
PI: Howard Safran, MD  
Site: Rhode Island Hospital
Learn more about this study

LS-P-Regeneron
A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies – Protocol R2810-ONC-1423.
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital

Gynecologic

Ovarian 

LS-P-Trap001: A Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital

Learn more about this study 

LS-P-CHUGAI: A phase 1 dose escalation and cohort expansion study ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors 
PI: Howard Safran, MD  
Site: Rhode Island Hospital
Learn more about this study

LS-P-Regeneron
A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies – Protocol R2810-ONC-1423.
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital

Head and Neck

LS-P-JSBA: A Phase I Study of LY2801653 in Patients with Advanced Cancer
 
PI: Ariel Birnbaum, MD 
Sites: Rhode Island Hospital, The Miriam Hospital
 
Learn more about this study

LS-P-Trap001: A Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital
 

LS-P-CHUGAI: A phase 1 dose escalation and cohort expansion study ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors 
PI: Howard Safran, MD  
Site: Rhode Island Hospital
Learn more about this study

LS-P-Regeneron
A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies – Protocol R2810-ONC-1423.
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital

Kidney

LS-P-Trap001: A Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital
 

LS-P-CHUGAI: A phase 1 dose escalation and cohort expansion study ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors
PI: Howard Safran, MD  
Site: Rhode Island Hospital
Learn more about this study

LS-P-Regeneron
A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies – Protocol R2810-ONC-1423.
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital

Leukemia 

Acute myelogenous leukemia (AML)

LS-P-CASCADE: A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)
PI: John Reagan, MD
Site:  Rhode Island Hospital
Learn more about this study  

Lung

LS-P-GO29537: A phase III, multicenter, randomized, open-label study evaluating the efficacy and safety of MPDL3280A (Anti-PD-L1 Antibody) in combination with Carboplatin + Nab-Paclitaxel for chemotherapy-naive patients with stage IV non-squamous non-small cell lung cancer 
PI: Humera Khurshid, MD 
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study 

BrUOG L301: Xofigo following frontline-line chemotherapy for patients with non-small cell lung cancer and bone metastases 
PI: Angela Taber, MD 
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study

BrUOG 317: Nivolumab and ablation for patients with advanced non-small cell lung cancer (NSCLC) progressing after at least one prior therapy for metastatic disease: A Brown University Oncology Research Group Phase II Study 
PI: Howard Safran, MD 
Sites: Rhode Island Hospital, The Miriam Hospital, Newport Hospital
Learn more about this study 

LS-P-STABLE-MATES: Joint Lung Cancer Trialist’s Coalition (JoLT – Ca) a randomized phase III study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in high risk patients with stage I non-small cell lung cancer (NSCLC), The STABLE-MATES Trial 
PI: Thomas DiPetrillo, MD 
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study

LS-P-Trap001: A Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital
 
CTSU E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
PI: Ariel Birnbaum, MD
Sites: Rhode Island Hospital, The Miriam Hospital, and Newport Hospital
 

LS-P-MALC: A phase III, open-label, randomized study to investigate the efficacy and safety of Atezolizumab MPDL3280A (anti-PD L1 antibody) compared with best supportive care following adjuvant cisplatin based chemotherapy in PD 
PI: Humera Khurshid, MD 
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study 

LS-P-M14-360: A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo Controlled Study of the Efficacy and Tolerability of Veliparib in Combination with Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects with Stage III Non-Small Cell Lung Cancer (NSCLC)
PI: Thomas DiPetrillo, MD
Sites: Rhode Island Hospital, The Miriam Hospital
 

LS-P-CHUGAI: A phase 1 dose escalation and cohort expansion study ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors 
PI: Howard Safran, MD  
Site: Rhode Island Hospital
Learn more about this study

LS-P-Regeneron
A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies – Protocol R2810-ONC-1423.
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital
 

Lymphoma

LS-P-CC-486-DLBCL-001: A phase one, open-label, multicenter trial of oral Azacitidine (CC-486) plus R-CHOP in subjects with high risk (IPI 3 Or More) previously untreated diffuse large B-cell lymphoma or grade 3B follicular lymphoma
PI: John Reagan, MD
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study

Non-Hodgkin's Lymphoma

 

LS-P-CC-486-DLBCL-001: A phase one, open-label, multicenter trial of oral Azacitidine (CC-486) plus R-CHOP in subjects with high risk (IPI 3 Or More) previously untreated diffuse large B-cell lymphoma or grade 3B follicular lymphoma
PI: John Reagan, MD
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study

 

Melanoma

LS-P-Trap001: A Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital

Learn more about this study

Uveal Melanoma

LS-P-JSBA: A phase I study of LY2801653 in patients with advanced cancer

PI: Ariel Birnbaum, MD
Site: Rhode Island Hospital
Learn more about this study

LS-P-Regeneron
A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies – Protocol R2810-ONC-1423.
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital

Multiple Myeloma

BrUOG M299- Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First- Line Treatment of Multiple Myeloma:
A Phase II Brown University Oncology Group Study
PI: Eric Winer, MD                                 
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study

Pancreatic

BrUOG P-295: A phase II adjuvant FOLFOX-A for resected pancreatic cancer study
 
PI: Howard Safran, MD
 
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study

BrUOG P-292: FOLFOX-A for metastatic pancreatic cancer: a phase II Brown University Oncology Research Group trial 
PI: Howard Safran, MD 
Sites: Rhode Island Hospital, The Miriam Hospital, Newport Hospital
Learn more about this study   

RTOG 0848: A phase III trial evaluating both Erlotinib and Chemoradiation as adjuvant treatment for patients with resected head of pancreas adenocarcinoma 
PI: Howard Safran, MD 
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study

LS-P-CHUGAI: A phase 1 dose escalation and cohort expansion study ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors 
PI: Howard Safran, MD  
Site: Rhode Island Hospital
Learn more about this study

LS-P-Regeneron
A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies – Protocol R2810-ONC-1423.
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital

Prostate

LS-P-ADXS142-03: A phase 1-2 dose-escalation and safety study of ADXS31-142 alone and of ADXS31-142 in combination with Pembrolizumab (MK-3475) in patients with previously treated metastatic castration-resistant prostate cancer 
PI: Anthony Mega, MD 
Site: The Miriam Hospital
Learn more about this study

LS-P-CHUGAI: A phase 1 dose escalation and cohort expansion study ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors
PI: Howard Safran, MD  
Site: Rhode Island Hospital
Learn more about this study

LS-P-Regeneron
A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies – Protocol R2810-ONC-1423.
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital
 
A phase III, multicenter, randomized study of atezolizumab (anti-pd L1 antibody) in combination with enzalutamide versus enzalutamide alone in patients with metastatic castration resistant prostate cancer after failure of an androgen synthesis inhibitor and failure of, ineligibility for, or refusal of a taxane regimen.
PI: Anthony Mega, MD
Site: The Miriam Hospital
Learn more about this study
 

LS-P-CO39303
A phase III, randomized, double-blind, placebo-controlled, multicenter trial testing ipatasertib plus abiraterone plus prednisone/prednisolone, relative to placebo plus abiraterone plus prednisone/prednisolone in adult male patients with asymptomatic or mildly symptomatic, previously untreated, metastatic castrate-resistant prostate cancer
PI: Anthony Mega, MD
Site: The Miriam Hospital
Learn more about this study

Rectal

BrUOG R-302: BYL719, Capecitabine and Radiation for rectal cancer: A Brown University Oncology Research Group phase I study  
PI: Howard Safran, MD  
Sites: Rhode Island Hospital, The Miriam Hospital
Learn more about this study  

LS-P-CHUGAI: A phase 1 dose escalation and cohort expansion study ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors
PI: Howard Safran, MD  
Site: Rhode Island Hospital
Learn more about this study

LS-P-Regeneron
A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies – Protocol R2810-ONC-1423.
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital

Stomach

BrUOG 265: Testing the addition of 5-iodo-2-pyrimidinone-2’-deoxyribose (IPdR) to radiation therapy to treat advanced gastrointestinal cancer 
PI: Timothy Kinsella, MD 
Site: Rhode Island Hospital
Learn more about this study

LS-P-JSBA is a study for patients with advanced gastric cancer or cholangiocarcinoma. The main purpose of this study is to find out what effects both good and bad that the addition of LY2801653 (an investigational drug) to the standard treatment has on the advanced cancer.
PI: Ariel Birnbaum, MD
Sites: The Miriam Hospital, Rhode Island Hospital
LS-P-POST: A study for patients with advanced gastroesophageal cancer. The main purpose of this study is to find out how the cancer responds to MSB0010718C (an investigational drug) and the side effects both good and bad.
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital
 
LS-P-Javelin 100:  A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital

Learn more about this study 

LS-P-CHUGAI: A phase 1 dose escalation and cohort expansion study ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors
PI: Howard Safran, MD  
Site: Rhode Island Hospital
Learn more about this study

LS-P-Regeneron
A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies – Protocol R2810-ONC-1423.
PI: Howard Safran, MD
Sites: Rhode Island Hospital, The Miriam Hospital
 

LS-P-JSBF
A randomized, double-blind, phase 2 study of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine as first-line treatment in patients with advanced or metastatic biliary tract cancer
PI: Rimini Breakstone, MD
Sites: Rhode Island Hospital and The Miriam Hospital
Learn more about this study